NeuroCME

This activity is expired and is no longer available for CME credit.

ARTICLECME

Changing Perspectives on the Role of the Immune System in Multiple Sclerosis Pathology, Differentiation, and Targeted Therapies

Author(s)/Faculty: Prof. Hans-Peter Hartung, MD, FRCP, FAAN, FANA; Giancarlo Comi, MD; Patricia K. Coyle, MD, FAAN, FANA; Stephen L. Hauser, MD; Prof. Xavier Montalban, MD, PhD
Release Date: 9/13/2016Expiration Date: 9/12/2017
Credit Type: CMENumber of Credits: 0
Content Type: MultimediaProvider: Vindico Medical Education
Multiple sclerosis (MS), a progressive, immune-mediated inflammatory disease, with debilitating clinical symptoms and worsening of disease activity over time. Multiple sclerosis is characterized by variable clinical courses: relapsing-remitting (RRMS), primary progressive (PPMS), and secondary progressive (SPMS). The differentiation of RRMS from PPMS has been challenging for neurologists, as both diseases share commonalities. Over the last several decades, treatment options have been developed for their effects, mostly on T cells, in the pathogenesis of the disease. Recent evidence has shown that B cells and humoral immunity also play a key role in MS pathogenesis. Early initiation of treatment is imperative to delay progression and provide the best possible outcomes. In this highly interactive CME activity, leading neurologists will review current theories and evidence regarding the immunopathogenesis of MS and assess the mechanisms of action, safety, and efficacy of new therapeutic agents, as well as the latest best practices when using selective high-efficacy agents to treat MS.